The aesthetic world descended on Monaco in late March. At AMWC 2026, the major injectable makers laid out their newest data across toxins, fillers, and regenerative treatments, a useful map of where the field is heading.
The Aesthetic and Anti-Aging Medicine World Congress (AMWC) ran March 26 to 28, 2026 in Monaco, one of the field marquee scientific meetings. Major manufacturers used it to present new data across neuromodulators, hyaluronic acid fillers, and regenerative biostimulators, signaling a year defined by whole-face treatment and skin-quality science.
If January and February set the regulatory headlines for 2026, late March was when the science showed up in volume.
AMWC Monaco is among the largest global aesthetic congresses, and the 2026 edition offered a broad snapshot of injectable innovation.
Galderma presented updates spanning its injectable portfolio, including economic and clinical posters on the liquid neuromodulator relabotulinumtoxinA, consensus recommendations for its use in the upper face, regenerative data on poly-L-lactic acid, and hyaluronic acid studies for areas such as the temple, chin, and décolletage, plus the role of biostimulators and fillers in menopause-related skin changes. Allergan Aesthetics, an AbbVie company, presented 21 evidence-based e-posters, including five on the investigational type-E neurotoxin trenibotulinumtoxinE and real-world data positioning onabotulinumtoxinA as a foundation for multimodal treatment plans.
Taken together, the program reflected the field current direction: combining modalities rather than relying on a single product, treating the whole face and beyond, and folding regenerative and skin-quality approaches into mainstream practice. Much of the data was investigational or congress-stage, presented to inform clinicians rather than to announce new U.S. approvals.
For consumers, congress coverage is an early, neutral read on what may eventually reach a provider menu, and on how thinking is evolving, toward layered, individualized plans rather than one-size treatments. It is also a reminder that posters and presentations are scientific communication, not regulatory clearance; many treatments discussed at AMWC are not yet FDA-approved in the United States.
Watch which AMWC datasets translate into U.S. regulatory filings and which remain region-specific. The recurring 2026 themes, liquid toxins, whole-face fillering, and biostimulator-led regeneration, are likely to shape provider conversations through the year. For patients, the practical takeaway is to ask providers what evidence supports a proposed treatment and whether the specific product is FDA-approved for the intended use, rather than assuming congress visibility equals availability.